AIDS Activists Sue Trump Administration Over Allegedly Hidden Terms in $1.4 Billion Gilead HIV Drug Settlement

An AIDS activist organization has filed a lawsuit targeting the Trump administration for refusing to disclose a research and development agreement that underpinned a major settlement with Gilead Sciences over patents for HIV prevention drugs. The legal action intensifies scrutiny over what critics say is insufficient transparency surrounding a deal that resolved a six-year dispute over taxpayer-funded scientific contributions to Gilead's blockbuster drugs Truvada and Descovy.

The underlying conflict originated when the previous Trump administration sued Gilead, alleging the company infringed Centers for Disease Control and Prevention patents by using government-funded academic research as the foundation for its HIV prevention medications. Federal officials accused Gilead of ignoring CDC scientist contributions, overstating its own role in drug development, and declining a licensing agreement despite repeated offers—while generating hundreds of millions in revenue from research underwritten by public funds. The settlement, which concluded the litigation, has now drawn fresh challenge from activists who argue the administration violated disclosure requirements by keeping the associated R&D agreement secret.

The lawsuit places the administration under renewed pressure to justify the terms of a settlement that critics contend may have allowed Gilead to retain disproportionate benefit from federally supported science. Activists warn that hidden agreements between the government and pharmaceutical companies could set problematic precedents for how taxpayer-funded discoveries are commercialized. The case is likely to attract attention from public health advocates and congressional oversight watchers seeking clarity on whether the settlement adequately protected the government's intellectual property interests.